![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EMA Awards Orphan Drug Designation to Loxo Oncology for LOXO-101
EMA Awards Orphan Drug Designation to Loxo Oncology for LOXO-101
The European Medicines Agency has blessed Loxo Oncology with orphan drug designation for LOXO-101, designed for the treatment of patients with soft tissue sarcoma.
LOXO-101 is being developed to treat patients with cancers containing abnormalities involving the tropomyosin receptor kinases.
Upcoming Events
-
21Oct